Implantica (IMP) Q2 2025 earnings summary

Executive summary

• Five-year pivotal study results for RefluxStop published, showing superior outcomes and safety versus existing treatments, with high patient satisfaction.

• U.S. FDA approval process for RefluxStop is in its final stages, with inspections scheduled and a decision expected before year-end.

• Expansion in Europe continues, with 19 centers in Spain and NICE recommending RefluxStop for certain patients in the U.K., paving the way for broader adoption.

• Production ramp-up underway, with 10,000 devices ordered and new manufacturing tools developed for the U.S. market.

• Cash and short-term investments stood at €56.3m at period end, with no interest-bearing debt.

Financial highlights

• Net sales for Q2 were €433,000, a 22% decrease year-over-year, mainly due to clinics focusing on enrolling patients in a new randomized clinical trial.

• Adjusted gross margin was 90% for Q2 (vs. 91% prior year); H1 margin rose to 94% (from 91%).

• Operating loss for Q2 was €4.53m, down 23% year-over-year, with H1 loss at €8.70m.

• Net loss for Q2 was €5.45m; H1 net loss was €8.21m.

• Equity ratio increased to 98% (from 96% prior year); equity at €92.8m.

Outlook and guidance

• FDA approval for RefluxStop is anticipated before year-end or early next year, with U.S. launch preparations well underway.

• Revenue in Europe expected to accelerate as reimbursement improves, especially in the U.K. following NICE recommendations.

• Randomized controlled trial (RCT) for RefluxStop versus Nissen fundoplication is commencing, with results expected within 1–1.5 years.

• Revenue impact from RCT launch expected to ease as patient recruitment stabilizes.

• Long-term growth expected from U.S. launch, expanded reimbursement, and global adoption.